


Ridogrel

Cat. No.:	HY-A0221	
CAS No.:	110140-89-1	
Molecular Formula:	C ₁₈ H ₁₇ F ₃ N ₂ O ₃	
Molecular Weight:	366.33	
Target:	Prostaglandin Receptor	
Pathway:	GPCR/G Protein	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (272.98 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
1 mM		2.7298 mL	13.6489 mL	27.2978 mL
5 mM		0.5460 mL	2.7298 mL	5.4596 mL
10 mM		0.2730 mL	1.3649 mL	2.7298 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Ridogrel (R 68070) is an orally active combined thromboxane A₂ synthetase inhibitor and thromboxane A₂/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities^{[1][2][3]}.

In Vitro

In rats, R 68 070 (1.25 mg/kg orally, -2 h) singly prolongs tail bleeding times as much as a combination of TXA₂ synthetase inhibition (dazoxiben 10 mg/kg) and TXA₂/prostaglandin endoperoxide receptor blockade (BM 13177 40 mg/kg). In dogs, the compound reduces coronary thrombosis induced by electrical damage (1.25 mg/kg i.v.) and prevents the evolution of occlusion/reperfusion-induced arrhythmias into ventricular fibrillation (2.5 mg/kg i.v.)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. De Clerck F, et al. R 68 070: thromboxane A₂ synthetase inhibition and thromboxane A₂/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. *Thromb Haemost.* 1989;61(1):43-49.

[2]. Di Perri T, et al. Ridogrel, una nuova molecola antiaggregante piastrinica a doppio meccanismo d'azione. Profilo farmacologico e clinico [Ridogrel, a new platelet

antiaggregant molecule with a double mechanism of action. A pharmacological and clinical pro

[3]. Carty E, et al. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14(6):807-817.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA